Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks

Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks

Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks

Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.

Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.

Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion

Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.

Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks